COMPLETEDPHASE3

Dose Response Trial of Pergolide for Cocaine Dependence - 1

Dose Response Trial of Pergolide for Cocaine Dependence

NCT00000248•Medical University of South Carolina

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of pergolide for treatment of cocaine dependence.

Eligibility

Age

21 - 50 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Please contact site for information.

Locations (1)

Medical University of South Carolina

Charleston, South Carolina, United States

Key Dates

Start Date

February 1, 1996

Last Updated

May 16, 2018

Conditions

Cocaine-Related Disorders

Interventions

Pergolide

DRUG

Neurocircuit Strategy to Decrease Cocaine Cue Reactivity

NCT04155632

Cocaine-Related Disorders

View study

COMPLETEDPHASE2

Targeting Anhedonia in Cocaine Use Disorder

NCT02773212

Cocaine-Related DisordersAnhedonia

View study

COMPLETEDEARLY_PHASE1

Brain Mechanisms in Young Adults

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 16, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

NCT03606473

Cocaine-Related Disorders

View study

TERMINATEDPHASE1